by | Jul 27, 2026 | Ansstas, George, Chen, David
— Published date: 7/28/2026
Value Proposition: Synergistic combination of intratumoral oncolytic therapy and MEK inhibition for treating metastatic melanoma.
Technology Description
Researchers at Washington University in St. Louis have developed a highly effective combination therapy using two …
by | Jun 1, 2026 | DeSelm, Carl
— Published date: 6/2/2026
Value proposition: CAR-engineered cDC1 cells (syngeneic or allogeneic) that stably express a proprietary, modular chimeric antigen receptor and demonstrate strong in vivo efficacy against solid tumors, including immunologically ‘cold’ tumors.
Technology Desc…
by Clarissa | Apr 28, 2026 | Cabanski, Christopher, Fields, Ryan, Maher, Christopher, Ryan, Silva-Fisher, Jessica
Publication date: 4/28/2026 Value Proposition: Non-coding RNA as a novel biomarker and therapeutic target for treating colon cancer. Technology Description Researchers at Washington University in St. Louis have developed a novel non-coding RNA, named RAMS11, as a...
by | Apr 20, 2026 | Brestoff Parker, Jonathan, Kim, Brian, Mack, Madison
— Published date: 4/21/2026
Value Proposition: IL-15 superagonist that utilizes a companion diagnostic to treat atopic dermatitis.
Technology Description
Researchers at Washington University in St. Louis have developed a treatment strategy for atopic dermatitis that uses an IL-15 superagonist, al…
by | Mar 12, 2026 | DiAntonio, Aaron, Geisler, Stefanie, Mao, Xianrong, Milbrandt, Jeffrey, Summers, Daniel
— Value Proposition: This invention uses a novel gene therapy that blocks the axon degeneration typical of neurodegenerative diseases.
Technology Description
Researchers at Washington University in St. Louis have developed a new strategy for treatment of neurodegenerative diseases with axonopathy.…